Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Shares Outstanding (2016 - 2025)

Corcept Therapeutics' Shares Outstanding history spans 7 years, with the latest figure at $107.8 million for Q4 2022.

  • For Q4 2022, Shares Outstanding rose 1.79% year-over-year to $107.8 million; the TTM value through Dec 2022 reached $107.8 million, up 1.79%, while the annual FY2022 figure was $107.8 million, 1.79% up from the prior year.
  • Shares Outstanding for Q4 2022 was $107.8 million at Corcept Therapeutics, roughly flat from $107.6 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $116.7 million in Q4 2020 and bottomed at $105.9 million in Q4 2021.
  • The 5-year median for Shares Outstanding is $115.0 million (2018), against an average of $113.2 million.
  • The largest annual shift saw Shares Outstanding rose 1.91% in 2020 before it decreased 9.25% in 2021.
  • A 5-year view of Shares Outstanding shows it stood at $115.0 million in 2018, then fell by 0.42% to $114.5 million in 2019, then increased by 1.91% to $116.7 million in 2020, then decreased by 9.25% to $105.9 million in 2021, then grew by 1.79% to $107.8 million in 2022.
  • Per Business Quant, the three most recent readings for CORT's Shares Outstanding are $107.8 million (Q4 2022), $107.6 million (Q3 2022), and $106.7 million (Q2 2022).